Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,945,621 protect, and when does it expire?

Patent ► Subscribe protects VIMOVO and is included in one NDA. There has been one Paragraph IV challenge on Vimovo.

This patent has twelve patent family members in twelve countries.

Summary for Patent: ► Subscribe

Title:	Method for treating a patient at risk for developing an NSAID-associated ulcer
Abstract:	The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.
Inventor(s):	Ault; Brian (Wilmington, DE), Hwang; Clara (Wilmington, DE), Orlemans; Everardus (Chapel Hill, NC), Plachetka; John R (Chapel Hill, NC), Sostek; Mark (Wilmington, DE)
Assignee:	Pozen Inc. (Chapel Hill, NC) Horizon Pharma USA, Inc. (Deerfield, IL)
Application Number:	12/822,612
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Patented / Exclusive Use
Horizon Pharma Usa	VIMOVO	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	022511-002	Apr 30, 2010	AB	RX	Yes	No	► Subscribe	► Subscribe	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
Horizon Pharma Usa	VIMOVO	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	022511-001	Apr 30, 2010	AB	RX	Yes	Yes	► Subscribe	► Subscribe	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country	Document Number	Estimated Expiration
Australia	2010263304	► Subscribe
Canada	2764963	► Subscribe
China	102481293	► Subscribe
Eurasian Patent Organization	201290026	► Subscribe
European Patent Office	2445499	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

DrugPatentWatch Database Preview